JunD is involved in the antiproliferative effect of Δ9-tetrahydrocannabinol on human breast cancer cells
Open Access
- 5 May 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 27 (37), 5033-5044
- https://doi.org/10.1038/onc.2008.145
Abstract
It has been recently shown that cannabinoids, the active components of marijuana and their derivatives, inhibit cell cycle progression of human breast cancer cells. Here we studied the mechanism of Δ9-tetrahydrocannabinol (THC) antiproliferative action in these cells, and show that it involves the modulation of JunD, a member of the AP-1 transcription factor family. THC activates JunD both by upregulating gene expression and by translocating the protein to the nuclear compartment, and these events are accompanied by a decrease in cell proliferation. Of interest, neither JunD activation nor proliferation inhibition was observed in human non-tumour mammary epithelial cells exposed to THC. We confirmed the importance of JunD in THC action by RNA interference and genetic ablation. Thus, in both JunD-silenced human breast cancer cells and JunD knockout mice-derived immortalized fibroblasts, the antiproliferative effect exerted by THC was significantly diminished. Gene array and siRNA experiments support that the cyclin-dependent kinase inhibitor p27 and the tumour suppressor gene testin are candidate JunD targets in cannabinoid action. In addition, our data suggest that the stress-regulated protein p8 participates in THC antiproliferative action in a JunD-independent manner. In summary, this is the first report showing not only that cannabinoids regulate JunD but, more generally, that JunD activation reduces the proliferation of cancer cells, which points to a new target to inhibit breast cancer progression.This publication has 29 references indexed in Scilit:
- The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation through a Lipid Raft-Mediated MechanismMolecular Pharmacology, 2006
- A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiformeBritish Journal of Cancer, 2006
- Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast CarcinomaThe Journal of pharmacology and experimental therapeutics, 2006
- 2-Arachidonoylglycerol Stimulates Activator Protein-1-dependent Transcriptional Activity and Enhances Epidermal Growth Factor-induced Cell Transformation in JB6 P+ CellsOnline Journal of Public Health Informatics, 2005
- AP-1: a double-edged sword in tumorigenesisNature Reviews Cancer, 2003
- Promoter Specificity and Biological Activity of Tethered AP-1 DimersMolecular and Cellular Biology, 2002
- Cannabinoid-receptor-independent cell signalling by N-acylethanolaminesBiochemical Journal, 2001
- Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesisOncogene, 1999
- Transformation by ras modifies AP1 composition and activityOncogene, 1997
- Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblastsOncogene, 1997